Yes, the standard prophylactic regimen is 400 mg (one tablet) taken once weekly, beginning 1-2 weeks before entering a malaria-endemic area and continuing for four weeks after leaving. Take the dose with food to improve absorption and reduce stomach upset.
An initial ophthalmologic exam is recommended before starting therapy. After five years of continuous use-or sooner if you have a high cumulative dose-annual eye exams are advised to detect early retinal changes.
Both belong to the same antimalarial class, but hydroxychloroquine is generally better tolerated and has a lower risk of retinal toxicity. It is the preferred agent for autoimmune diseases in the UK.
Yes, antacids containing calcium, magnesium, or iron can decrease hydroxychloroquine absorption. To avoid this, separate the dosing of antacids and hydroxychloroquine by at least two hours.
Moderate alcohol consumption does not produce a direct interaction, but excessive drinking can worsen liver function and increase overall medication toxicity. Discuss your alcohol intake with your prescriber.
A mild rash is common and may resolve without intervention. However, if the rash spreads, is accompanied by fever, or shows signs of blistering, seek medical attention promptly as it could signal a serious hypersensitivity reaction.
Hydroxychloroquine does not appear to significantly impair the immune response to most vaccines, but because it modulates immune activity, timing of vaccination should be coordinated with your rheumatologist or primary care physician.
Having a pacemaker does not automatically contraindicate hydroxychloroquine, but if you have underlying cardiac conduction issues or are on other QT-prolonging drugs, an ECG evaluation is advisable before starting therapy.
Clinical benefits often become noticeable after 4-12 weeks of consistent therapy, though some patients may require longer to achieve optimal disease control.
In the UK, hydroxychloroquine prescribed for approved indications such as SLE, rheumatoid arthritis, or malaria prophylaxis is generally available on the NHS prescription formulary, subject to NHS prescribing guidelines.
Hydroxychloroquine contains Hydroxychloroquine Sulfate as its active component. It belongs to a class of medications known as antimalarials, but in the United Kingdom it is most commonly prescribed for autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Hydroxychloroquine is supplied as oral pill tablets in strengths of 200 mg and 400 mg and is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Hydroxychloroquine is a weak base that accumulates in acidic cellular compartments-particularly lysosomes and endosomes. By raising the pH inside these organelles, the drug interferes with several immune-related processes:
These actions together diminish the over-active immune response seen in diseases like lupus and rheumatoid arthritis. The antimalarial effect arises from the same increase in endosomal pH, which prevents the malaria parasite Plasmodium from surviving inside red blood cells.
Onset of clinical benefit for autoimmune disease usually requires several weeks, reflecting the time needed for immune modulation and tissue repair. The drug’s half-life is long (approximately 40 days), leading to steady-state concentrations after around two months of continued therapy.
Hydroxychloroquine is MHRA-approved for the following indications in the UK:
These approved uses are based on robust clinical trial data and long-term safety experience. The medication is not approved for COVID-19, influenza, or any other viral infection.
Early in the COVID-19 pandemic, hydroxychloroquine was investigated as a potential antiviral agent. Large, well-controlled randomized trials-including the RECOVERY trial in the UK-demonstrated no clinical benefit for hospitalized patients or those with early disease. Moreover, the studies highlighted an increased risk of cardiac arrhythmias, especially when combined with other QT-prolonging agents.
Regulatory status: Hydroxychloroquine is not approved for the prevention or treatment of COVID-19 in the UK. Off-label use for this purpose is discouraged and should only occur within a controlled clinical trial setting.
Limited case series have examined hydroxyhydroxychloroquine for conditions such as certain dermatologic disorders (e.g., cutaneous lupus) and as an adjunct in some chronic pain syndromes. These uses lack sufficient high-quality evidence to support routine prescribing and are considered experimental.
Off-label prescribing for any condition requires careful medical supervision, individualized risk assessment, and clear documentation.
These effects are usually mild and improve with continued use or dose adjustment.
General advice: Always inform your pharmacist and prescriber of all medications, supplements, and herbal products you are using.
Autoimmune disease (SLE, RA):
Initial dose often 200 mg once daily or 400 mg on day 1 followed by 200 mg daily.
Maintenance dose typically 200-400 mg daily, adjusted to clinical response and tolerability.
Malaria prophylaxis:
400 mg (one tablet) once weekly, taken with a meal, starting 1-2 weeks before travel and continued for 4 weeks after leaving the endemic area.
Malaria treatment:
800 mg (two 400 mg tablets) as a single dose, followed by 400 mg at 6 hours, 24 hours, and 48 hours after the initial dose.
Note: The above regimens reflect common practice; your prescriber will tailor the dose to your specific situation, especially if you have renal or hepatic impairment.
If you miss a dose, take it as soon as you remember unless it is near the time of the next scheduled dose. Do not double up without consulting a healthcare professional.
Hydroxychloroquine is usually stopped abruptly under medical guidance. No tapering is required for most patients, but abrupt cessation may lead to disease flare-ups in autoimmune conditions. Discuss a plan with your prescriber to manage underlying disease activity.
This article provides educational information about Hydroxychloroquine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
